Glyxambi Dosage/Direction for Use

The recommended starting dose is Empagliflozin + Linagliptin (GLYXAMBI) 10 mg/5 mg (empagliflozin 10 mg/linagliptin 5 mg) once daily. In patients tolerating Empagliflozin + Linagliptin (GLYXAMBI) 10 mg/5 mg once daily and requiring additional glycaemic control, the dose can be increased to Empagliflozin + Linagliptin (GLYXAMBI) 25 mg/5 mg (empagliflozin 25 mg/linagliptin 5 mg) once daily. Empagliflozin + Linagliptin (GLYXAMBI) can be taken with or without food and at any time of day.
Patients with renal impairment: Empagliflozin + Linagliptin (GLYXAMBI) is not recommended for use in patients with eGFR <30 mL/min/1.73 m² (see Precautions).
No dose adjustment is required for patients with eGFR ≥30 mL/min/1.73 m².
Patients with hepatic impairment: No dose adjustment is recommended for patients with hepatic impairment.
Elderly patients: No dosage adjustment is recommended based on age.
Paediatric population: The safety and effectiveness of Empagliflozin + Linagliptin (GLYXAMBI) in children below 18 years of age have not been established. Empagliflozin + Linagliptin (GLYXAMBI) is not recommended for use in patients under 18 years of age. Available data on the single components are described in Pharmacology: Pharmacodynamics: Clinical Trials and Pharmacokinetics under Actions.
Combination therapy: When Empagliflozin + Linagliptin (GLYXAMBI) is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia (see Interactions and Adverse Reactions).
Missed dose: If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.